ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1342	National Cancer Institute	Html	en	Secondhand Smoke and Cancer	A fact sheet that summarizes the studies on the health effects of exposure to environmental (secondhand) tobacco smoke.	safe level 0.379875 passive smoke 0.502001 Human Services 0.468341 nonsmoking adults 0.357216 secondhand tobacco smoke 0.68104 U.S. Department 0.464191 lung cancer 0.378247 Cancer Progress Report 0.355171 burning tobacco product 0.42493 secondhand smoke 0.997055 Environmental Health Hazard 0.364487 Tobacco Control Monograph 0.372592 tobacco smoke 0.693112 U.S. Surgeon General 0.402428 Tobacco Smoke Causes 0.494425 tobacco products 0.362817 nationwide health promotion 0.362703 Environmental Tobacco Smoke—ETS 0.377837 Environmental Protection Agency 0.465583 contain harmful chemicals 0.358856 health effects 0.390654 disease prevention agenda 0.353662 United States 0.418836 National Toxicology Program 0.432935 health promotion 0.395997	U.S. Environmental Protection 0.431643 sudden infant death 0.405056 public places 0.357277 U.S. National Toxicology 0.366163 infant death syndrome 0.405701 heart disease 0.378172 smoking 0.358862 National Cancer Institute 0.4772 smoke cause cancer 0.529335 heart disease deaths 0.35595 Respiratory Health Effects 0.361324 tobacco product 0.437535 secondhand smoke exposure 0.747052 sinus cavity cancer 0.360979 health 0.407857 tobacco smoke cause 0.527224 environmental tobacco smoke 0.625449 Chronic Disease Prevention 0.389 lung cancer deaths 0.360096 Surgeon General 0.4042 Public Health Service 0.390186 involuntary smoke 0.507716 ear infections 0.356303 testing indoor air 0.35347	CLICK HERE
1358	National Cancer Institute	Html	en	Gastrointestinal Complications (PDQ®)–Health Professional Version	Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed.	complete bowel obstruction 0.653864 stool 0.625324 gastrointestinal tract 0.642496 Oncol Nurs Forum 0.609323 cancer-related diarrhea 0.733825 refractory diarrhea 0.683452 diarrhea management 0.729396 total bowel rest 0.605453 diarrhea events 0.682702 bone marrow transplantation 0.599048 PUBMED Abstract 0.628255 octreotide acetate 0.600127 bowel lumen 0.596911 abdominal pain 0.618725 progressive bowel obstruction 0.651874 normal bowel function 0.623449 bowel obstruction 0.807553 Support Care Cancer 0.590223 acute diarrhea 0.731833 traveler’s diarrhea 0.692746 regimen-related diarrhea 0.681582 small bowel 0.642547 somatostatin analog octreotide 0.636325 depot octreotide 0.600959	chemotherapy-induced diarrhea 0.813859 malignant bowel obstruction 0.739577 cancer care 0.622581 cancer treatment-induced diarrhea 0.733195 severe diarrhea 0.723383 irritable bowel syndrome 0.602845 patients 0.752157 Clin Oncol 0.637052 cancer patients 0.616135 radiation-induced diarrhea 0.788656 neurogenic bowel dysfunction 0.61585 diarrhea 0.944656 inflammatory bowel disease 0.603068 bone marrow 0.600992 gastrostomy tube 0.601159 Nutr Clin Pract 0.61137 pelvic radiation-induced diarrhea 0.726181 octreotide 0.694845 extraluminal bowel lesions 0.625405 Delayed diarrhea 0.692341 fecal impaction 0.682249 et al. 0.624888 Subcutaneous octreotide 0.602593	CLICK HERE
1805	National Cancer Institute	Html	es	Tratamiento del cáncer de ano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.	Anal Cancer Trial 0.489207 results from 0.31371 John M 0.347549 with external radiotherapy 0.314904 anal canal 0.794085 combined modality therapy 0.350825 Trial Working Party 0.324488 randomized intergroup study 0.336989 Radiation Therapy Oncology 0.354467 perianal epidermoid cancers 0.314329 Radiat Oncol Biol 0.493627 anal intraepithelial neoplasia 0.3483 Natl Cancer Inst 0.358284 Flam M 0.355801 epidermoid carcinoma 0.391708 patients with 0.3347 radiation therapy 0.487367 preoperative multidisciplinary therapy 0.316168 squamous carcinoma 0.31988 intraepitelial anal ii–iii 0.32888 Krall JM 0.319145 Cancer Trial Working 0.342892 estadio ii 0.314589 Pajak TF 0.321788 Therapy Oncology Group 0.342392	with anal squamous 0.330697 anal carcinoma 0.555894 patients with carcinoma 0.314283 adjuvant combined modality 0.322897 combined with chemotherapy 0.336207 Oncology Group study 0.357157 Cancer Research 0.342768 therapy combined with 0.337029 Definitive irradiation 0.321135 randomised ukcccr anal 0.326366 interim report 0.31903 versus radiotherapy 0.314135 Clin Oncol 0.342577 Sischy B 0.347382 Oncol Biol Phys 0.504444 UK Co-ordinating Committee 0.321139 anal cancer 0.987825 definitive nonsurgical treatment 0.344247 optimal radiation 0.320998 advanced anal canal 0.329424 UKCCCR Anal Cancer 0.435954 implantation combined with 0.313892 anal canal carcinoma 0.398943 Doggett RL 0.318887	CLICK HERE
1859	National Cancer Institute	Html	es	Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe.	Neck Cancer Cooperative 0.13741 pharyngeal cancers 0.150792 Pfister DG 0.13468 pyriform sinus treated 0.135606 Cancer Res 0.206838 Radiat Oncol Biol 0.237454 DeVita VT Jr 0.131516 pyriform sinus 0.18629 Natl Cancer Inst 0.207961 radiation therapy 0.254373 Head Neck Surg 0.418544 carcinoma treated with 0.123784 squamous carcinoma 0.207808 with surgery 0.155955 Mendenhall WM 0.309662 Head Neck 0.426668 estadio iv 0.131056 neck squamous 0.149286 Parsons JT 0.126343 radioterapia preoperatoria versus 0.132896 sinus treated with 0.147408 treated with surgery 0.145993 radioterapia posoperatoria 0.168742 Oral Oncol 0.128712 Hendrickson FR 0.131539	treatment based 0.121981 Otolaryngol Head Neck 0.206433 hypopharyngeal carcinomas 0.157978 radiotherapy with 0.12894 with poor prognosis 0.124956 hypopharyngeal squamous 0.152628 Spindle cell carcinoma 0.12283 Clin Oncol 0.138573 combined with neck 0.126143 Oncol Biol Phys 0.243047 combining radiotherapy with 0.126277 estadio iii 0.184936 radiotherapy with surgery 0.128843 Treat Options Oncol 0.123145 radioterapia adyuvante posoperatoria 0.177283 European Organization 0.12179 neck cancer 0.973991 undifferentiated carcinomas 0.126856 quimioterapia neoadyuvante 0.630349 locally advanced 0.131399 Hansen O 0.125257 induction chemotherapy 0.134893 neck carcinoma 0.172184 squamous cell carcinoma 0.867141	CLICK HERE
1864	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	mutación jak2 0.0546285 Campbell PJ 0.0405614 primary myelofibrosis 0.131535 polycythaemia vera 0.093088 Health Organization classification 0.0291993 have myelofibrosis with 0.0314259 Mesa RA 0.119444 or calr mutation 0.036061 with nonmutated jak2 0.0536842 myeloproliferative neoplasms 0.261769 thousand patients with 0.0269901 with polycythemia vera 0.195275 Vera Study Group 0.0949279 leucemia mielógena 0.0351738 polycythemia vera with 0.109106 stem cell transplantation 0.0588703 transfusion-dependent patients with 0.0283801 patients with philadelphia 0.0316383 myeloproliferative disorders 0.146587 vera with jak2v617f 0.038469 calr mutation 0.0482163 Leuk Lymphoma 0.0369689 with essential thrombocythemia 0.0866875 patients with 0.725855 Verstovsek S 0.0388869	essential thrombocythemia 0.44083 patients with primary 0.0790517 metaplasia with myelofibrosis 0.0416952 with myeloid metaplasia 0.913374 essential thrombocythaemia 0.0355199 CALR mutation status 0.0373736 Organization classification system 0.0297845 with primary myelofibrosis 0.0630012 jak2 or calr 0.0410501 sudores nocturnos 0.0340921 leucemia aguda 0.0337979 patients with myelofibrosis 0.203296 vera with recombinant 0.0414353 Thiele J 0.0617064 patients with polycythemia 0.16042 myelofibrosis with 0.580226 polycythemia vera 0.713605 Tefferi A 0.30746 thrombocythemia with substantially 0.0550099 Polycythemia Vera Study 0.106061 with substantially different 0.0495287 Clin Oncol 0.190573 neoplasms with nonmutated 0.0489374 essential thrombocythemia with 0.102281	CLICK HERE
1887	National Cancer Institute	Html	es	Tratamiento del carcinoma de células de Merkel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de células de Merkel.	Cutan Pathol 0.403221 skin cancer 0.402076 critical review with 0.401107 cell carcinoma showing 0.404318 review with guidelines 0.401112 Australian Merkel cell 0.404544 Distinct merkel cell 0.404503 Am Acad Dermatol 0.404485 cell polyomavirus dna 0.402185 Curr Opin Oncol 0.401201 Cell Carcinoma Information 0.404476 7th ed 0.401399 Rockville Merkel Cell 0.404613 ganglios linfáticos centinela 0.405335 SEER Program 0.402412 cell carcinoma tumors 0.407605 Coit DG 0.402335 into merkel cell 0.405013 Seattle Cancer Care 0.401199 Cancer Care Alliance 0.401228 Natl Cancer Inst 0.40149 Merkel tumours 0.402858 patients with merkel 0.422467 with cutaneous merkel-cell 0.401294 Arch Dermatol 0.401934	cutaneous merkel-cell carcinoma 0.404932 with merkel cell 0.435163 Invest Dermatol 0.401806 neuroendocrine-merkel cell carcinoma 0.404323 Cancer Staging Manual 0.402011 patients from 0.401403 Surg Oncol 0.411261 Nghiem P 0.404669 New York 0.401702 merkel cell carcinoma 0.998942 specimens from patients 0.401221 Clin Oncol 0.41408 Dermatol Surg 0.40166 CCM recién 0.401912 Carcinoma Group 0.402481 cell carcinoma demographics 0.418051 primary merkel 0.405524 Trabecular carcinoma 0.402756 American Joint Committee 0.401365 merkel cell polyomavirus 0.432273 cell carcinoma after 0.40431 cell polyomavirus infection 0.402124 merkel-cell carcinoma 0.40673 from patients with 0.402629	CLICK HERE
3425	National Cancer Institute	Html	es	Estrés psicológico y el cáncer	Hoja informativa que describe los efectos del estrés en el cuerpo, los resultados de investigaciones sobre la relación entre el estrés y el cáncer e información sobre cómo superar el estrés.	Sood AK 0.430056 care standards from 0.338514 determinadas hormonas 0.324248 Antoni MH 0.367904 tumor biology 0.324968 metastatic switch 0.319814 Dahmoush L 0.320856 psychological distress 0.325611 DeGeest K 0.320069 Dy SM 0.323303 Discovery Medicine 0.320658 estrés resultante 0.422988 biobehavioral signaling pathways 0.342266 peor calidad 0.321062 immune system 0.320953 McDonald PG 0.320742 Host factors 0.321766 Supportive Oncology 0.337163 Cox BF 0.320273 Psychological stress 0.329279 elevated tumor 0.324862 print march 0.323271	biobehavioral perspective 0.328519 familiar cercano 0.324843 tejidos adiposos mamarios 0.340834 sympathetic nervous system 0.335164 Lutgendorf SK 0.581508 Martinez KA 0.323343 ratones portadores 0.329629 PubMed Abstract 0.950792 killer cell activity 0.340076 carcinoma patients 0.32286 meta-analytic study 0.320949 Social isolation 0.322911 Lei X 0.320438 Priceman SJ 0.320893 peores resultados 0.32033 Clinical Oncology 0.442906 primary breast 0.321519 Segerstrom SC 0.320085 Psychological Bulletin 0.326317 largo tiempo 0.321876 bloqueadores beta 0.426953	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE